Quest Diagnostics has reported that the OVA1 blood test has been found to be a more accurate detector of ovarian cancer than the medically accepted CA 125 blood test in a clinical study.
In 516 women scheduled for surgery for an ovarian mass, 94% of malignancies were accurately detected by OVA1, compared to 77% by CA 125.
In premenopausal women the detection rate was 91% for OVA1 versus 58% for CA 125.
An analysis by third parties on behalf of Quest Diagnostics showed that ovarian masses effect an estimated one million women in the US each year, and has led to as many as 300,000 surgeries.
OVA1 is the first test cleared by the US Food and Drug Administration for aiding the pre-surgical evaluation of ovarian mass for cancer, and also is the first protein-based in vitro diagnostic multi-variate index assays.